Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities

Click here to view online. Add this email to your safelist.

23 December 2021

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retains neutralisation activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new authentic ‘live’ virus neutralisation data from both University College Oxford, UK and Washington University School of Medicine, St. Louis, US.

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.